Corticosteroid Eyedrops Market Report 2026

The corticosteroid eyedrops market size has grown strongly in recent years. It will grow from $10 billion in 2025 to $10.67 billion in 2026 at a compound annual growth rate (CAGR) of 6.8%. The growth in the historic period can be attributed to limited availability of corticosteroid formulations, reliance on hospital pharmacies, increasing ophthalmic surgeries, growing awareness of ocular inflammation treatment, traditional prednisolone and dexamethasone usage.

The corticosteroid eyedrops market size is expected to see strong growth in the next few years. It will grow to $13.69 billion in 2030 at a compound annual growth rate (CAGR) of 6.4%. The growth in the forecast period can be attributed to development of advanced combination therapy eyedrops, rise in pediatric ophthalmology treatments, growth of online pharmacy distribution, increasing adoption of patient-centric delivery devices, regulatory approvals for novel corticosteroid formulations. Major trends in the forecast period include rising prevalence of eye disorders requiring anti-inflammatory therapy, growing preference for combination therapy eyedrops, increased adoption of pediatric-friendly formulations, expansion of online and retail pharmacy channels, focus on improving drug stability and patient compliance.

The increasing prevalence of eye diseases is anticipated to drive the growth of the corticosteroid eyedrops market in the coming years. Eye diseases include a wide range of conditions that affect visual health and eye function, potentially leading to impaired vision or blindness if not appropriately treated. The rising incidence of eye diseases is largely attributed to increased screen time, which causes digital eye strain and contributes to conditions such as dry eye syndrome and blurred vision. Corticosteroid eyedrops are widely used in the management of eye diseases because they reduce inflammation and help alleviate symptoms such as redness, swelling, and ocular discomfort. For instance, in May 2024, according to a report published by the Joint Strategic Needs Assessment, a UK-based community health center, approximately 2 million people in the UK were living with some degree of sight loss, a figure projected to rise to 2.7 million by 2030. Therefore, the growing prevalence of eye diseases is contributing to the expansion of the corticosteroid eyedrops market.

Major companies operating in the corticosteroid eyedrops market are prioritizing regulatory approvals to broaden their product portfolios and improve market penetration. Regulatory approvals involve formal authorization from health authorities, confirming that corticosteroid eyedrops meet established safety, efficacy, and quality requirements prior to commercialization and clinical use. For instance, in March 2024, Formosa Pharmaceuticals Inc., a Taiwan-based pharmaceutical company, in collaboration with AimMax Therapeutics, a US-based pharmaceutical company, received approval from the US Food and Drug Administration for clobetasol propionate ophthalmic suspension 0.05% (APP13007) for the treatment of postoperative inflammation and pain following ocular surgery. Developed using Formosa’s APNT nanoparticle technology, this corticosteroid formulation enables effective drug delivery with a convenient twice-daily dosing regimen for 14 days without the need for tapering. Clinical studies demonstrated strong anti-inflammatory efficacy, positioning it as a valuable addition to available corticosteroid therapies for managing postoperative ocular inflammation and pain. As the first ophthalmic corticosteroid containing clobetasol and the first new steroid approved in this category in more than 15 years, it represents a significant advancement in ocular corticosteroid treatment.

In June 2025, Harrow Inc., a US-based ophthalmic pharmaceutical company, acquired the exclusive US commercial rights to Byqovi (clobetasol propionate ophthalmic suspension) 0.05% from Formosa Pharmaceuticals Inc. for an undisclosed sum. Through this acquisition, Harrow aims to expand its surgical ophthalmology portfolio by incorporating a newly FDA-approved high-potency corticosteroid for the management of postoperative inflammation and pain. Formosa Pharmaceuticals Inc. is a Taiwan-based biotechnology company focused on ophthalmology and oncology, utilizing proprietary nanoparticle formulation technologies.

Major companies operating in the corticosteroid eyedrops market are Pfizer Inc., AbbVie Inc., Novartis AG, Alcon Inc., Bausch Health Companies Inc., Sun Pharmaceutical Industries Ltd., Cipla Ltd., Santen Pharmaceutical Co. Ltd., Lupin Limited, Zydus Lifesciences Limited, Glenmark Pharmaceuticals Ltd., Alkem Laboratories Ltd., Sunways Pvt. Ltd., FDC Limited, Eurocrit Labs International Pvt. Ltd., Entod Pharmaceuticals Pvt. Ltd., Akorn Pharmaceuticals Inc., Kala Pharmaceuticals Inc.

North America was the largest region in the corticosteroid eyedrops market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the corticosteroid eyedrops market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the corticosteroid eyedrops market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have influenced the corticosteroid eyedrops market by increasing costs of imported active pharmaceutical ingredients (APIs) and specialized delivery devices like dropper bottles and punctal plugs. Segments such as combination therapy eyedrops and advanced topical formulations are most affected, particularly in Asia-Pacific regions like India and China. This has led to higher production costs and slower market expansion. On the positive side, tariffs encourage local API manufacturing, domestic production of delivery devices, and innovation in cost-effective formulations.

The corticosteroid eyedrops market research report is one of a series of new reports that provides corticosteroid eyedrops market statistics, including corticosteroid eyedrops industry global market size, regional shares, competitors with a corticosteroid eyedrops market share, detailed corticosteroid eyedrops market segments, market trends and opportunities, and any further data you may need to thrive in the corticosteroid eyedrops industry. This corticosteroid eyedrops market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Corticosteroid eyedrops are prescription ophthalmic medications that contain corticosteroids, which are potent anti-inflammatory agents used to reduce eye swelling, redness, and irritation. These eyedrops are commonly prescribed for the treatment of various ocular conditions such as uveitis, allergic conjunctivitis, and inflammation following eye surgery or injury, helping to prevent tissue damage and support faster healing.

The main product types of corticosteroid eyedrops include topical corticosteroid eyedrops, systemic corticosteroid eyedrops, and combination therapy eyedrops. Topical corticosteroid eyedrops are liquid formulations applied directly to the eye surface to alleviate inflammation. They are available in different delivery formats, including dropper bottles, spray formulations, ointments and gels, and punctal plugs, and are distributed through channels such as hospital pharmacies, retail pharmacies, online pharmacies, and others. These products are used for both adult and pediatric applications and serve a broad range of end users, including hospitals, specialty clinics, community pharmacies, and online pharmacies.

The corticosteroid eyedrops market consists of sales of low-potency corticosteroid eyedrops, ointments, subconjunctival injections, antibiotic formulations, and periocular injections. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.